Answers are grounded in this paper and cite their sources.
The myosin heavy chain 9 ( MYH9 ) gene encodes non-muscle myosin heavy chain IIA (NMHC IIA), a key effector linking the actin cytoskeleton, mechanical force generation, and signal transduction. The role of MYH9 in cancer is markedly dependent on cell type, gene dosage, subcellular localization, and molecular context. Although most studies have reported tumor-promoting effects, a limited number of in vivo genetic models support a tumor-suppressive role in specific settings, such as squamous cell carcinoma; p53 status may further influence the direction of this activity. Here, we review MYH9 structure, expression regulation, and the distinctions between its intracellular and extracellular forms. We critically compare evidence for its tumor-promoting and tumor-suppressive roles, distinguishing direct functional validation from preclinical associations and bioinformatic correlations. We further summarize how non-coding RNA-mediated regulation, proteostasis, and cytoskeletal remodeling relate to therapy resistance and discuss the direct and indirect effects of MYH9 on immune cells and the tumor microenvironment. Finally, we assess the translational potential of MYH9 in terms of isoform selectivity, tumor-specific delivery, normal-tissue toxicity, and combination therapy. Current evidence is insufficient to establish MYH9 as a clinically validated predictive biomarker for immunotherapy or as a broad-spectrum therapeutic target. Its clinical application will require mechanistically rigorous in vivo studies and prospective clinical validation.
No takes yet. Share an insight, caveat, or question.
Ji et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: